Spotlight intensifies on cancer drug reimbursement

Pharmaceutical manufacturers have long been under scrutiny for the methodsthey employ in marketing their products to physicians. Now, increasing concernthat drug makers are winning physician favor by deeply discounting chemotherapymedicines is placing those physicians under the microscopes of federal andstate authorities.

Related Content:

Drug TherapyPractice Management

Urologic group partnership to offer access to in-house PCR lab testing

Breaking down the CMS 2023 final rule for urologists

Expert provides in-depth analysis of 4 types of annuity enhancements